Can HRT Cause Cancer?

Cancer risk is one of the most common fears women bring to conversations about HRT, and it deserves a direct and honest answer. Yes, HRT does carry a slightly increased risk of breast cancer, particularly with longer-term use. This risk is real and should be part of your decision-making process. But context matters enormously. The risk is small in absolute terms, it varies significantly depending on the type of HRT you take and for how long, and for many women the benefits of HRT, including quality of life, bone protection, and cardiovascular protection, genuinely outweigh the risk. For others, particularly those with specific personal or family risk factors, the calculus looks different. This is a decision to make with your doctor, with full information, not one to make in fear based on headlines or outdated data.

What causes this?

Estrogen stimulates the growth and division of breast cells. This is a normal part of its role in the body throughout reproductive life. In the context of HRT, supplemental estrogen provides additional stimulation to breast tissue, which over time can promote the growth of breast cancer cells that might otherwise remain dormant or grow very slowly.

The increased risk is most clearly associated with combined HRT, meaning estrogen plus progestogen. This is because progestogens, particularly synthetic progestins like medroxyprogesterone acetate, further stimulate breast cell proliferation. Studies including the Million Women Study and the Women's Health Initiative suggest that combined HRT increases breast cancer risk more than estrogen-only HRT. The estrogen-only arm of the Women's Health Initiative, which followed women who had undergone hysterectomy, actually showed no statistically significant increase in breast cancer risk and in some analyses a small protective effect.

The type of progestogen may matter significantly. Micronised progesterone, the body-identical form, appears to have less breast cancer risk than synthetic progestins based on observational studies, particularly French observational data. This has led many menopause specialists to favour body-identical HRT formulations, though head-to-head randomised trial data comparing these specific formulations for breast cancer outcomes are limited.

Duration of use influences the risk. Risk increases with years of use and decreases after stopping HRT. Women who take HRT for less than 5 years have a smaller risk increase than those who take it for a decade or more. Once you stop, your excess risk declines over the following years, generally returning close to baseline within 5 to 10 years of stopping.

Your personal baseline risk matters too. Age, family history of breast cancer, body weight, alcohol consumption, dense breast tissue, and whether you have had previous breast biopsies all influence your starting risk. HRT's effect is additive to that baseline. Two women taking the same HRT may have very different absolute risk increases depending on their individual risk profiles.

How long does this typically last?

The increased breast cancer risk associated with HRT develops gradually over years rather than appearing immediately. Most studies indicate that any meaningful increase in risk appears after 5 or more years of use. Shorter-term use of 2 to 3 years carries a smaller risk increment, though it is not zero.

Once you stop HRT, your excess risk begins to decrease. Within 5 years of stopping, breast cancer risk returns to close to the level it would have been if you had never taken HRT. This means that if you take HRT for symptom relief during the peak perimenopause years and then stop, your lifetime risk is not dramatically elevated.

Endometrial cancer risk is different. Estrogen-only HRT in women who have an intact uterus significantly increases endometrial cancer risk, which is why progestogen is always prescribed alongside estrogen for women who have not had a hysterectomy. When progestogen is taken appropriately, it protects the endometrium and brings endometrial cancer risk back to baseline or even below baseline.

What actually helps?

Having a thorough conversation with your doctor about your personal and family risk factors before starting HRT is essential. A doctor who specialises in menopause can help you calculate your approximate baseline breast cancer risk and assess how much HRT might add to that. Tools like the Tyrer-Cuzick model can estimate your 10-year and lifetime breast cancer risk based on personal and family history.

Choosing the lowest effective dose of HRT reduces your exposure and any associated risk. The principle of minimum effective dose is well-established in hormone therapy, and there is no benefit to taking more than you need. Many women can manage their symptoms at doses lower than they initially start on, particularly as they move further past menopause.

Favoring body-identical estradiol and micronised progesterone over synthetic alternatives is a reasonable choice given the available evidence. While the evidence is not definitive, observational studies suggest a more favourable breast cancer risk profile for these formulations. Your doctor can prescribe these if they are appropriate for your situation.

Maintaining a healthy weight is one of the most powerful modifiable risk factors for breast cancer. Excess body fat produces estrogen through aromatisation, meaning overweight and obese women already have higher baseline estrogen exposure. Reaching and maintaining a healthy weight reduces breast cancer risk independent of HRT.

Limiting alcohol is similarly impactful. Alcohol increases breast cancer risk directly. Even moderate drinking, one to two drinks per day, is associated with a measurable increase in risk. Cutting back on alcohol reduces your cancer risk across multiple pathways.

Regular exercise reduces breast cancer risk. Consistent aerobic activity of 150 minutes or more weekly is associated with meaningful risk reduction.

Continuing with regular breast cancer screening while on HRT is non-negotiable. Annual or biennial mammograms allow cancers to be caught early when they are most treatable. If you notice any changes in your breasts, including lumps, skin changes, nipple discharge, or asymmetry, report them to your doctor promptly.

What makes it worse?

Taking HRT in doses higher than necessary increases cumulative hormone exposure and any associated risk without providing additional benefit. Using the highest dose that relieves symptoms rather than the lowest effective dose is not the optimal approach.

Not getting regular mammograms while on HRT means any breast changes may be detected later than necessary. HRT can increase breast density, which can make mammograms harder to read, so annual rather than biennial screening may be advisable in some cases. Discuss frequency with your doctor.

Continuing HRT indefinitely without periodic reassessment of whether you still need it increases cumulative risk unnecessarily. Most guidelines suggest reviewing the need for HRT annually and discussing whether the benefits continue to outweigh risks at each review.

Having a personal history of breast cancer significantly changes the HRT risk calculation. Some breast cancer survivors can use certain forms of HRT after specific types of cancer treatment, but this requires specialist evaluation. Do not start HRT after a breast cancer diagnosis without specialist oncology input.

When should I talk to a doctor?

HRT is associated with a slightly increased breast cancer risk, particularly with combined HRT used for more than 5 years. This risk is real but small in absolute terms, and it reverses over time after stopping. For many women, the quality of life improvements and other health benefits of HRT outweigh this risk, particularly when body-identical formulations are used at the lowest effective dose. For others, the risk calculation looks different. The most important thing is making a fully informed decision with your doctor, based on your individual risk factors, symptoms, and values, not based on fear or on ignoring the evidence. Regular breast screening throughout HRT use is essential.

This content is for informational purposes only and does not replace medical advice. Always consult your healthcare provider about your specific situation.